Policymakers, federal agencies, the media and others continue to raise concerns over how pharmacy benefit managers (PBMs) put profits ahead of patients. The FTC’s latest report on PBMs unveiled more evidence of ways these powerful middlemen are inflating costs and squeezing out independent pharmacies with their abusive tactics.
At the same time, voters continue to voice their concerns over PBM practices and call on policymakers to act.
Here are some examples.
Driving up costs
- “As a registered nurse, I’ve seen how difficult it can be for patients struggling to access and afford the critical care, treatments and prescription drugs they need due to the harmful practices of Pharmacy Benefit Managers (PBMs). These financial burdens only create more stress for patients, many of whom are already fighting for their lives. This is not how America’s healthcare system should work, and it is long past time for Congress to protect patients from these harmful policies.” – Amanda from New York
- “PBMs control roughly 80% of the prescription drug marketplace to-day. Instead of using that power for good, these groups use it to control when and where patients can access the life-saving medications they need. Broken PBM policies can also force patients to pay higher out-of-pocket expenses. Policymakers should lead on this issue and…rein in and reform harmful PBM practices that threaten patients as soon as possible.” – Mary from California
Limiting access
- “PBM policies can make that process of accessing prescription medications harder because they’re able to limit where you can pick up your prescriptions using nonsensical patient ‘steering’ policies. In short, these groups just have too much power and control over patients and the entire prescription drug marketplace. It’s about time for lawmakers to shine a light on the shameful pharmacy benefit managers (PBM) practices that threaten patient access and contribute to the lack of pharmacy access for rural patients and communities.” – Michelle from Nevada
- “This is an issue that impacts tens of millions of Americans, regardless of political affiliation, and I cannot understand what is taking lawmakers in Washington so long to address it…These insurer-owned groups only care about protecting and increasing their profits by any means necessary, even if that means threatening access and increasing prescription drug costs and out-of-pocket expenses…They should not be able to throttle access to prescriptions by using harmful policies like step therapy and prior authorization….” – Callie from Montana
Refusing to share savings
- “As healthcare middlemen, PBMs exploit vulnerable patients, taking advantage of the 340B program and refusing to pass down savings to patients. During the negotiation process, PBMs secure sizeable prescription drug rebates directly from manufacturers. These rebates should be passed down to patients to help reduce their out-of-pocket burden at the pharmacy. However, PBMs are far more likely to withhold these savings to further inflate their profit margins.” – Terry from Minnesota
Driving out independent pharmacies
- “PBMs also regularly steer customers towards larger chains in which they are financially vested. Vertical integration of PBMs with their own pharmacy chains creates conflicts of interest…[which] undermines the financial stability and competitive viability of independent pharmacies, threatening their existence and reducing healthcare options for patients. PBM reform is essential if we are to avoid further closures of independent pharmacies in Oregon.” – Victor from Oregon
A recent Morning Consult/PhRMA poll builds on these themes showing 81% of Americans are concerned that PBMs influence what medicines patients get and control what patients pay at the pharmacy. The same poll found 84% of Americans agree that policymakers should focus on cracking down on abusive practices by health insurance companies and other middlemen that make it harder to get the care they need.
Patients are fed up with middlemen putting profits before their health care. Policymakers must fix the broken system and take on the middlemen that are limiting access, driving up costs and driving out competition.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
What AARP isn’t telling seniors about MFN
Policymakers should improve patient access and reject price controls
Insurers blame GLP-1s for rising costs. The data tells a different story.
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
Nearly 1 in 4 patients initially denied access to IRA medicines
Message to USAging: Providers are raising concerns about coverage barriers
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
Survey confirms too many insured Americans face barriers to reliable health care
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
Hospitals drive nearly 80% of the U.S. health spending gap
No hassle, hidden markups or fees: AmericasMedicines.com
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
Separating fact from fiction in the medicine supply chain
50-state poll says Americans are concerned that hospital markups hurt patients
Three things you should know from the insurer CEO congressional hearings
Can’t get your medicine? Don’t count on your insurer.
Stop, collaborate and re-evaluate: ICER’s pricing report
California’s landmark PBM crackdown: A wake-up call for reform
Middlemen mark up drug prices and keep discounts meant for you
Putting patients first: Breaking down barriers to care
Direct purchase programs can lower costs for patients
PBMs say they want lower priced medicines, so why don’t they cover them?
Historic biopharmaceutical investments: A prescription for America’s future
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
PBMs are hiding hurdles to essential care
New study: PBMs and commercial insurers are quietly blocking prescription access
North Carolina puts patients first with rebate pass-through law
PBMs, not patents, are blocking access to lower-cost medicines
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
Foreign first pricing schemes don’t address why Americans pay more
The AHIP premium dollar corrected (again)
PBMs launch new ad campaign to block reforms
When middlemen own it all, patients pay the price
3 myths critics get wrong about intellectual property
New report finds more abuse of 340B program by hospitals and drug middlemen
A closer look at how health care consolidation drives up patient costs, creates barriers to care
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
Congress Keeps PBMs in the Hot Seat
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
New policy agenda charts solutions for a healthier America
A successful PhRMA Forum highlights our commitment to a healthier America
Wrapping up the J.P. Morgan Healthcare Conference
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
PhRMA CEOs Tee Up Next Week's Health Care Conference
New study: Entities that don’t make medicines get half of what is spent on those medicines
Three things to know about 340B contract pharmacies
The PBM industry's desperate attempt to stop reform
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
Reimagining patient access through meaningful policy reform
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Guest Post: My health care vote
Insurers continue shifting more costs on to patients
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
ICYMI: The powerful companies driving local drugstores out of business
Hispanic Heritage Month: Fighting for Hispanic patients
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
Key voter insights two months from Election Day
Patient priorities in the 2024 election
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
FTC report confirms PBMs profit at the expense of patients
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
ICYMI: What patients care about this election year
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
ICYMI: Health care policy should be driven by patients, not politics
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
Ongoing federal probes shed light on PBM and insurer practices
WTAS: The consequences of consolidation and vertical integration
Insurance data: PBM reform has no material impact on premiums
ICYMI: Voter priorities this election season
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
3 Takeaways from POLITICO’s Health Care Summit
PBMs using 340B program to drive profits at patients’ expense
Four years later, Maryland board still hasn’t delivered for patients
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
When it comes to the future of innovation, the ball is in policymakers’ court
How the 340B program became a PBM giveaway
ICYMI: When middlemen get in the way, it’s the patients who lose
Get the facts on PCMA’s newest attempt to avoid accountability
The IRA’s pill penalty threatens the future of oncology R&D
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
One year to Election Day: Four voter priorities to watch
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
New poll shows strong bipartisan support for PBM reform
4 truths about state government price setting
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
Word of the Month: AMR
New analysis shows PBMs use fees as a profit center
It’s PBMs, not patents, blocking competition
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Three things to know from the latest Patient Experience Survey
More than 60 researchers ask Congress to support innovation
ICYMI: PBM exec admits choosing profits over patients
Insulin: Key Facts on Access & Affordability
4 key facts on medicine prices and spending
4 Things to know about PhRMA’s new 50-state poll
Americans want state policymakers to lower out-of-pocket costs
New PhRMA ad campaign sheds light on PBM abuses
Policies need to address the growing threat of antimicrobial resistance
Three facts about health care spending
AHIP’s latest misinformation campaign & what it’s trying to hide
New global analysis shows patient access challenges around the world
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
States can support access to medicine as COVID-19 Public Health Emergency ends
Arkansas puts patients first with new share the savings law
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
Holding pharmacy benefit managers accountable
Stopping pharmacy benefit managers from “gaming the system”
Senate hearing to examine bipartisan reforms to rein in middlemen
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
In their own words: Financial barriers exacerbate access challenges for insured Americans
New data show how insurers and middlemen shift Rx costs onto patients
In their own words: Insured Americans struggle to navigate complex coverage
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
A key fact the White House is reluctant to admit
A key fact the White House is reluctant to admit
Navigating the patient experience: Burdens and barriers standing between patients and their care
Insulin and reconciliation
New survey: Voters seriously concerned about fine print in reconciliation bill
Myth vs. Fact: The Senate’s latest price setting proposal
The Senate’s latest price setting proposal will undermine U.S. economic growth
Celebrating Medicare’s 57th anniversary
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
The Senate’s latest price setting proposal will undermine: Our health care system
The Senate’s latest price setting proposal will undermine: American medical innovation
The Senate’s latest price setting proposal will undermine: Patient access to medicines
The Patient Perspective: Government price-setting harms patients
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
By the Numbers: Patients lose when the government sets prices
Patients win as West Virginia implements first-in-nation share the savings policy
3 things voters are concerned about when it comes to their health care coverage
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
New poll shows voters sounding the alarm on health insurance companies and PBMs
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
Analysis: States can help patients save nearly $1,000 annually on their medicines
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
Government price setting leaves behind families counting on new medicines
PhRMA submits comments urging CMS to withdraw coverage proposal
Medicaid 101: Three charts on access and spending
Government price setting won’t stop insurers from shifting costs to patients
New comments outline ways to counteract cost-shifting insurance trends
New study finds more than half of brand medicine spending goes to the supply chain and others
Making medicines more affordable: Preserving safety-net programs like 340B
Post-approval research save lives. Why is Congress trying disincentivize it?
A price control by any other name would still put patients at risk and threaten innovation
Making medicines more affordable: Making insurance work like insurance
Navigating the patient experience in the time of COVID-19
New poll shows Americans reject Medicare negotiation once they learn more about the policy
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
PhRMA releases 2021 industry profile
Four solutions Americans support to make health care more affordable
H.R. 3 threatens access to medicines, future innovation and American jobs
New insulin report highlights how incentives benefit middlemen, harm patients
Key facts: The final rebate rule will be a positive change for patients
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
Study finds middlemen excluded nearly 850 medicines from formularies this year
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Five key facts about the market for insulins
The PBM story you haven’t heard: Hidden fees quadrupled in two years
OptumRX: Sharing rebates with patients is “worth it”
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Advance price notification: A transparency measure that fails patients
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
A critical opportunity to prevent prescription drug abuse
Why won’t the insurance industry tell the truth about medicine costs?
340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
Trading fair means upholding the law: A focus on patents
Enforcing unmet trade obligations protects U.S. innovation
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
"WTAS: Voters voice concerns about PBM abuses, call on policymakers to act"
PBMs/Insurance
Policy Solutions
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
"WTAS: Voters voice concerns about PBM abuses, call on policymakers to act"